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The Underutilisation of Dual Antiplatelet Therapy in Acute Coronary Syndrome 
 
ABSTRACT 
 
Background: Despite guideline recommendation of dual antiplatelet therapy (DAPT) in 
treating ACS, DAPT is underutilized. Our objective was to determine independent predictors 
of DAPT non-prescription in ACS and describe pattern of DAPT prescription over time.   
 
Methods: Patients presenting to 41 Australian hospitals with an ACS diagnosis between 
2009 and 2016 were stratified according to discharge prescription with DAPT and single 
antiplatelet therapy (SAPT) or no antiplatelet therapy. Multiple stepwise logistic regression, 
accounting for within hospital clustering, was used to determine the independent predictors 
of DAPT non-prescription, defined as discharge with SAPT alone or no antiplatelet agent. 
 
Results: 8939 patients survived to discharge with an ACS diagnosis. Of these, 6294 (70.4%) 
patients were discharged on DAPT, 2154 (24.1%) on SAPT and 491 (5.5%) on no antiplatelet 
agent.  Independent predictors of DAPT non-prescription in the overall cohort were: in-
hospital CABG (OR 0.09, 95%CI 0.05-0.14), discharge with warfarin (0.10 (0.07-0.14)), in 
hospital major bleeding (0.48 (0.34-0.67), diagnosis of unstable angina (0.35, (0.27-0.45)), 
non-ST-elevation myocardial infarction (0.67 (0.57-0.78)) [both vs. ST-segment elevation 
myocardial infarction], in hospital atrial arrhythmia (0.72 (0.60-0.86)), history of 
hypertension (0.83 (0.73-0.94)) and GRACE high risk (0.83 (0.71-0.98)). There was an 
increase in prescription of DAPT and a shift towards ticagrelor over clopidogrel for ACS from 
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2013 to 2016 (p<0.0001), but no overall change in the frequency of DAPT prescription over 
the entire study period.  
 
Conclusion: This study revealed high-risk ACS subgroups who do not receive optimal DAPT. 
Strategies are necessary to bridge the treatment gap in ACS antiplatelet management. 
 
Keywords: Dual antiplatelet therapy, Acute Coronary Syndrome 
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The Underutilisation of Dual Antiplatelet Therapy in Acute Coronary Syndromes 
 
INTRODUCTION 
 
The benefit of dual antiplatelet therapy (DAPT) in patients presenting with ACS is both 
clinically important and unequivocal [1] . This is true for both ST-segment elevation acute 
coronary syndrome (STEACS) [2, 3] and non-ST elevation acute coronary syndrome 
(NSTEACS) [1]. However, there are treatment gaps in the management of patients with an 
ACS, with studies during the 2000’s reporting anywhere from 30% to 50% of ACS patients 
being discharged on single antiplatelet therapy [4, 5].   
 
Since that time, newer, more potent alternatives to clopidogrel have been shown to further 
improve outcomes across the spectrum of ACS [6, 7].  Yet as recently as 2012, a 
comprehensive Australian and New Zealand audit encompassing over 90% of hospitals 
across both countries showed that only 63% of ACS patients received a second antiplatelet 
agent at hospital discharge[8].  In all reported studies, one consistent observation was the 
difference between prescription of a second antiplatelet for patients following PCI 
(percutaneous coronary intervention), where rates were higher than for those undergoing 
CABG or medical management, despite a consistent accumulation of evidence supporting 
the use of these second agents in each of these contexts [9-11] 
  
There remains a significant risk of events following an ACS, with mortality in the 12-18 
months following an ACS reported to be 12.6%, and the composite rate of myocardial 
infarction, stroke or cardiovascular death to be 18.3%  [12, 13]. Therefore, there is a 
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continued need to improve clinical outcomes in patients with an ACS by bridging the gap in 
antiplatelet therapy prescription at hospital discharge [14]. Indeed, modelling studies have 
suggested that up to 10.9% of deaths by 6 months may be prevented through 
implementation of adenosine diphosphate (ADP) receptor antagonist therapy following an 
ACS[14].  
 
The aims were: first, to better understand the Australian practice of DAPT prescription at 
hospital discharge following acute coronary syndrome; second, to determine the 
independent predictors of DAPT non-prescription; and third, to evaluate the impact of the 
availability of newer ADP receptor antagonists on the pattern of prescription of DAPT over 
time.   
 
METHODS 
 
Study population 
This study reports individual patient data from the Australian CONCORDANCE (Cooperative 
National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events), an 
ongoing prospective registry, which has recruited patients from 41 hospitals since 2009.  
Methods for this study have been published [15] and are summarised briefly below.   
 
To be included in CONCORDANCE patients were at least 18 years of age, and presented with 
symptoms suggestive of coronary ischaemia together with either ECG changes, elevation of 
serum cardiac biomarkers of myocardial necrosis or documented coronary artery disease. 
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ACS events precipitated by non-cardiovascular co-morbidities such as anaemia or trauma 
(including Type 2 myocardial infarction) were excluded. The first 10–20 consecutive eligible 
patients were recruited from each site per month. Trained coordinators using standardised 
case report forms collected data. Demographic characteristics, medical history, presenting 
symptoms, biochemical and electrocardiographic findings, treatment practices, and a 
variety of hospital outcome data were collected.   Standardised definitions for all patient-
related variables and clinical diagnoses were used. This analysis included patients enrolled 
between 2009 and 2016 with a discharge diagnosis of confirmed ACS.  
 
Outcome measures 
 
The principal objective of the study was to determine the predictors of DAPT non-
prescription at discharge following admission for an ACS. DAPT was defined as discharge 
prescription with a combination of aspirin plus one of clopidogrel, prasugrel or ticagrelor. 
Single antiplatelet therapy (SAPT) was prescription at discharge with one of these agents 
alone. DAPT non-prescription at ACS discharge was defined as prescription of SAPT alone or 
no antiplatelet agent.  
 
Statistical analysis 
 
ACS patients discharged alive on DAPT, SAPT or no antiplatelet therapy were included in this 
analysis. Analyses were performed in the ACS population as a whole, as well as the 
subgroups of patients who were medically managed.  We also examined the pattern of 
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antiplatelet prescription according to year of admission.  Baseline patient demographics 
were compared between patients discharged with DAPT and SAPT/no antiplatelet agent 
following admission with ACS using the Rao-Scott chi-square test for categorical variables 
and univariable regression model for continuous variables, accounting for clustering of 
patients within hospitals. The frequency of DAPT prescription at discharge was determined 
for all patients and then also for those managed medically without PCI or CABG. Univariable 
unadjusted predictors were used in building a multivariable model to identify the 
independent predictors for non-prescription of DAPT at discharge. The covariates were 
added to the logistic regression model using stepwise selection. Missing values were present 
in <5% of the data. A 2-tailed alpha-level of 0.05 was considered the threshold for statistical 
significance for all tests. To account for within-hospital clustering, the regression models 
were built using a logistic generalized estimating equations method with exchangeable 
working correlation matrix, because patients at the same hospital are more likely to be 
similar and have similar responses relative to patients at other hospitals. SAS version 9.4  
(SAS Institute Inc., Cary, NC) was used for the statistical analysis.  
 
RESULTS 
 
Baseline characteristics 
 
This study included 8939 patients who survived to discharge with a final diagnosis of ACS. Of 
these, 6294 (70.4%) patients were discharged with DAPT, and 2645 (29.6%) were discharged 
with SAPT or no antiplatelet agent.  Of those receiving SAPT, the majority were given aspirin 
(89.5%), followed by clopidogrel (9.8%), then ticagrelor (0.6%) or prasugrel (0.1%) alone. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Those prescribed SAPT/no antiplatelet agent compared with those prescribed DAPT at 
discharge were older (p<0.0001) and of high GRACE risk (p<0.0001) with greater prevalence 
of comorbidities (Table 1).  
 
Table 1: Baseline characteristics for the overall cohort of patients admitted with ACS and 
survived to discharge. 
 
Variable Statistic/Level 
DAPT 
n=6294   
n (%) 
Other*  
n=2645 
n (%) 
Overall 
n=8939 
n (%) P-value 
Age (years) Mean 63.3 67.3 64.5 <0.0001 
 SD 13.28 13.22 13.39 . 
Sex Female 1642 (26) 938 (35) 2580 (29) <0.0001 
 Male 4652 (74) 1707 (65) 6539 (71) . 
GRACE risk score** Median (q1, 
q3) 
102.6 
(82.9, 
124.0) 
107.0 
(84.6, 
131.3) 
103.9 
(83.3, 
125.9) 
<0.0001 
GRACE risk score categories  Low 3485 (57) 1304 (51) 4789 (56) <0.0001 
 Intermediate 1849 (30) 805 (32) 2654 (31) . 
 High 739 (12) 441 (17) 1180 (14) . 
Previous myocardial infarction  1783 (28) 812 (31) 2595 (29) 0.003 
Previous angiographic coronary 
artery disease 
 2088 (33) 1008 (38) 3096 (35) 0.0003 
Previous Coronary Intervention  1399 (22) 464 (18) 1863 (21) <0.0001 
Previous CABG  641 (10) 368 (14) 1009 (11) <0.0001 
Prior diagnosis of CAD  1293 (21) 733 (28) 2026 (23) <0.0001 
Family history of CAD  2239 (36) 828 (31) 3067 (34) 0.0008 
Diabetes Mellitus  1614 (26) 818 (31) 2432 (27) <0.0001 
Hypertension  3719 (59) 1825 (69) 5544 (62) <0.0001 
Dyslipidaemia  3475 (55) 1586 (60) 5061 (57) 0.0002 
Congestive heart failure  363 (6) 300 (11) 663 (7) <0.0001 
Previous mechanical valve 
replacement  
 39 (1) 59 (2) 98 (1) <0.0001 
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Variable Statistic/Level 
DAPT 
n=6294   
n (%) 
Other*  
n=2645 
n (%) 
Overall 
n=8939 
n (%) P-value 
Chronic Renal Failure   441 (7) 299 (11) 740 (8) <0.0001 
Previous stroke or transient 
ischemic attack  
 376 (6) 251 (9) 627 (7) <0.0001 
Peripheral arterial disease  336 (5) 208 (8) 544 (6) <0.0001 
Smoking history Never 2145 (34) 1011 (38) 3156 (35) <0.0001 
 Ex-smoker 2108 (34) 1075 (41) 3183 (36) . 
 Current smoker 2020 (32) 554 (21) 2574 (29) . 
Previous major bleed  108 (2) 75 (3) 183 (2) 0.0006 
 
Data presented using non-missing data. *Other: discharge with SAPT or no antiplatelet at 
discharge, **GRACE score predicting risk of death and myocardial infarction in the six 
months after ACS presentation [16]. CABG: coronary artery bypass grafting surgery, CAD: 
coronary artery disease, DAPT: dual antiplatelet therapy, GRACE: Global registry of acute 
coronary events, SAPT: single antiplatelet therapy, SD: standard deviation.  
 
 
There was a difference in the rate of prescription of DAPT according to ACS diagnosis, 
whereby patients with STEMI were most likely and those with UA least likely to be 
prescribed DAPT (Table 2).   Furthermore, there was a gradient of prescription of DAPT 
associated with the presence and mode of revascularisation; patients undergoing PCI were 
most likely, those medically managed were intermediate, and those undergoing CABG least 
likely to be discharged on DAPT. In patients undergoing CABG, those prescribed SAPT or no 
antiplatelet compared to those prescribed DAPT were more likely to have a history of 
hypertension or to have been discharged with warfarin; to have a previous history of 
bleeding or to have in hospital major bleeding (table 4-6, supplementary data).    
 
It was noteworthy that more than 40% of the medically managed cohort were discharged 
on SAPT or no therapy (Figure 1a-b, supplementary data). 
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Table 2 ACS diagnosis, in hospital revascularisation strategy and events 
Diagnosis/Procedures/ 
Complications/ 
Discharge medication Level 
DAPT 
n=6294 
[%] 
Other*
n=2645 
[%] 
Overall 
n=8939 
n (%) P-value 
Diagnosis STEMI 2349 (37) 360 (14) 2709 (31) <0.0001 
 NSTEMI 3000 (49) 
1435 
(54) 
4435 (50) 
 
 UA 945 (15) 850 (32) 1795 (20)  
Percutaneous coronary 
intervention  4144 (66) 146 (6) 
 
4290 (48) <0.0001 
Fibrinolysis** 
 
776 (33) 141 (39) 917 (34) <0.0001 
Coronary artery bypass grafting  103 (2) 671 (25) 
 
774 (9) <0.0001 
Cardiogenic Shock   86 (1) 39(1) 125 (1) 0.6 
Congestive Failure   354 (6) 296 (11) 650 (7) <0.0001 
Renal Failure    210 (3) 176 (7) 386 (4) <0.0001 
Cardiac Arrest   128 (2) 37 (1) 165 (2) 0.005 
AV-Block   67 (1) 40 (2) 107 (1) 0.08 
Atrial arrhythmia   382 (6) 470 (18) 852 (10) <0.0001 
Sustained VT   90 (1) 46 (2) 136 (2) 0.2 
Stroke   20 (0.4) 21 (1) 41 (0.4) 0.0009 
Major Bleeding   367 (6) 324 (12) 691 (8) <0.0001 
 
Data presented using non-missing data. *Other: discharge with SAPT or no antiplatelet at 
discharge, **Values expressed as a percentage of patients admitted with STEMI. 
NSTEMI: non-ST elevation myocardial infarction, STEMI: ST elevation myocardial infarction, 
UA: unstable angina. 
 
 
Referral to cardiac rehabilitation and discharge medication 
 
Patients prescribed DAPT were more likely to have been referred for cardiac rehabilitation 
and to be discharged on other evidence based medications including angiotensin-converting 
enzyme inhibitors, statins and beta-blockers. ((Table 1, supplementary data). Warfarin was 
prescribed more frequently for patients on SAPT or no antiplatelet. 
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Independent predictors of DAPT non-prescription  
 
The independent predictors of DAPT non- prescription at discharge in the full cohort were: 
in-hospital CABG, discharge with warfarin, in hospital major bleeding, diagnosis of unstable 
angina or non-ST-elevation myocardial infarction [both vs. ST-segment elevation myocardial 
infarction], in hospital atrial arrhythmia, history of hypertension and GRACE high risk (0.83 
(0.71-0.98)). Factors predicting a greater likelihood of DAPT prescription were prior MI, in 
hospital PCI (percutaneous coronary intervention), previous coronary intervention and 
discharge with ACEI (angiotensin-converting enzyme inhibitor), beta-blocker or statin.  
[Figure 1(a)]. 
 
Medically managed patients 
 
Amongst those admitted with an ACS, 3922 (43.9%) patients were medically managed.  Of 
these, 2063 (52.6%) were prescribed DAPT and 1859 (47.4%) SAPT or no antiplatelet at 
discharge. Those prescribed SAPT or no antiplatelet compared with those prescribed DAPT 
at discharge were older (p<0.0001), of high GRACE risk (p=0.0006), had a history of 
congestive heart failure (p=0.04), previously undergone mechanical valve replacement 
(p<0.0001) and experienced greater in hospital congestive cardiac failure, atrial arrhythmia 
and major bleeding (table 2-3, supplementary data) 
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Independent predictors of DAPT non-prescription in the medically managed cohort 
 
The independent predictors of DAPT non-prescription at discharge amongst those medically 
managed included: discharge with warfarin, in hospital major bleeding, NSTEMI, unstable 
angina (both vs STEMI) and in hospital atrial arrhythmia. History of hypertension neared 
significance as an independent predictor of DAPT non-prescription [Figure 1(b)]. 
 
Antiplatelet prescription according to year of admission with ACS 
 
Overall there was no discernible trend (p=0.2) in the percentage of patients with DAPT and 
SAPT prescription between 2009 and 2016 [Figure 2(a)]. However, when the analysis was 
restricted to the years from 2013, there was evidence for an increasing trend in DAPT 
prescription (69.4% in 2013 to 78.4% in 2016, p<0.0001, test for trend). There was an 
absolute 12.9% increase in ticagrelor prescription over this time period (p<0.0001), and a 
modest 7.0% decrease in clopidogrel prescription. Prasugrel prescription for ACS remained 
low throughout the study period, with prescription rates not exceeding 5% (since availability 
of the drug in 2011).   
 
In the cohort of medically managed patients, there was a gradual decrease in DAPT 
prescription and increase in SAPT prescription between 2010 and 2013; this trend was 
reversed from 2013 to 2016 [Figure 2(b)]. There was an absolute 11.5% increase in 
ticagrelor prescription (p<0.0001), accompanied by a small 2.6% decline in clopidogrel 
prescription.  
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DISCUSSION 
 
This study describes patterns of DAPT use in a real world cohort of Australian ACS patients 
over a 7-year period. A gap in DAPT use was identified with an overall prevalence of 70.4% 
at discharge. The independent predictors of DAPT non-prescription at ACS discharge were: 
in-hospital CABG, discharge with warfarin, in hospital major bleeding, diagnosis of unstable angina 
or non-ST-elevation myocardial infarction [both vs. ST-segment elevation myocardial infarction], in 
hospital atrial arrhythmia, history of hypertension and GRACE high risk. Despite no overall 
changes in patterns of DAPT prescription in the overall study period, in more recent years 
from 2013 to 2016 there was an increasing trend in DAPT prescription, paralleled by a 
significant absolute increase in ticagrelor use. 
 
Although the 30% failure rate of DAPT prescription in ACS patients is contrary to the strong 
evidence base [1, 6, 7], these data are consistent with other representative local and 
international studies.  In the CRUSADE registry, use of clopidogrel was 73% during 2004 and 
2005[5].  The third EUROHEART survey conducted during 2007 reported discharge 
clopidogrel prescription of 76.4%.   More recently, the Australian and New Zealand 
SNAPSHOT ACS study representing >90% of hospitals across Australia and all hospitals in 
New Zealand, reported discharge prescription of a second antiplatelet drug in 63% of ACS 
patients[17].   
 
Patients undergoing PCI were most likely to receive DAPT, an observation consistently 
reported in other observational studies[5, 8], and reflects the accepted view of DAPT 
following coronary stenting for the vast majority of PCI patients.     
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Patients undergoing CABG were more likely to be prescribed SAPT or no antiplatelet agent, 
with a failure to initiate a second antiplatelet reflecting failure to apply secondary 
prevention therapies to this population in general [18, 19]. This perhaps occurs due to the 
usual discontinuation of an ADP receptor antagonist prior to surgery and concern of 
bleeding on the part of surgical teams.  A post-hoc analysis of the CURE trial supported the 
use of a second antiplatelet in the CABG, although most of the differential in events 
occurred in the pre-operative phase[9]. A substudy of patients who underwent CABG in the 
PLATO study, identified a significant reduction in cardiovascular death and total mortality 
with ticagrelor use as compared with clopidogrel administration, without any difference in 
CABG related major bleeding[10].  A most recent comprehensive review of the data 
including both randomised and observational data by the ACC/AHA writing group focussed 
on duration of DAPT therapy, endorsed therapy with DAPT in patients at hospital discharge 
following CABG[20].     
 
The non-prescription of DAPT was strongly associated with certain comorbidities. The failure 
to prescribe DAPT in those with hypertension may be related to concerns of bleeding 
complications, particularly intracranial bleeding, or may have reflected unmeasured or 
unreported comorbidities in this cohort. SAPT or no antiplatelet prescription was more likely 
in those with a history of previous bleeding, presumably due to concern of future bleeding 
with antiplatelet therapy. However aspirin alone reduces the risk of death or myocardial 
infarction by up to 50%[21], whilst increasing the risk of major bleeding by only 1-3%[1, 22].  
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Over 43% of our patients were not revascularised following their ACS presentation 
(medically managed cohort). Barely half of these patients were discharged on DAPT despite 
their higher GRACE risk score when compared to revascularised patients, closely matching 
the 54% reported in CRUSADE 2004-2005 [5]. A recent Italian registry study showed that at 
the time of discharge, DAPT was prescribed in 58.8% of medically managed patients [23]. 
Although the use of DAPT was pioneered in patients receiving coronary stents[24, 25], the 
medically managed ACS population experience comparable relative risk reduction to those 
receiving stents, which translates to an even greater absolute benefit because of their 
higher absolute risk[1].  Indeed this observation of greater absolute benefit with provision 
of therapies with greater antiplatelet potency among the medically managed patients is 
reinforced in the PLATO trial [7].    
 
In Australia, government funding of clopidogrel for all ACS patients was not available until 
early 2009[26] .  It was not surprising then, that earlier ACS registries in this country have 
shown use of this drug in the medically managed cohort to be low  (15-30%)[27].  However, 
even with government funding now available, the increase in uptake has been limited. Our 
findings suggest that DAPT non-prescription in this group is driven by concerns around atrial 
arrhythmia (presumably because of the potential for concomitant anticoagulant therapy), a 
history of major bleeding and discharge on warfarin.  However, these factors alone were 
relatively infrequent (individually <15% of this population) and do not explain the continued 
resistance to provision of a second antiplatelet to these high-risk patients. The under-
treatment of medically managed ACS patients with guideline recommended antiplatelet 
therapy is associated with poorer prognosis [28, 29]. 
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We observed little variation in the provision of DAPT during the first few years of the study, 
despite several large, well designed randomised trials early in this period strengthening the 
evidence base in the ACS population, and providing justification for the newer, more potent 
ADP receptor antagonist drugs, prasugrel and ticagrelor [6, 7].    
 
However from 2013, we did observe an increase in the use of DAPT, which paralleled 
increased prescription of ticagrelor, only partly offset by a reduction in the prescription of 
clopidogrel, with little use of prasugrel.  Reasons for this failure to adopt prasugrel 
potentially include the study design of TRITON-TIMI 38 [6] not being reflective of Australian 
practice, contraindication in patient subgroups (absolute with age >75 and relative for those 
with weight <60kg and history of stroke/TIA) due to increased risk of bleeding, and a 
apparent lack of benefit in medically managed ACS patients compared to clopidogrel [30].  
 
The lag in uptake of ticagrelor is less easy to understand.  This drug was approved and its 
use reimbursed by the Australian PBS (pharmaceutical benefits scheme) in February 2012.   
In a Greek ACS registry collecting data from Jan 2012 to Jan 2013, rates of discharge on 
clopidogrel and ticagrelor were comparable[31] in an ACS population undergoing PCI, 
suggesting Australian practice to be out of step with data from European cohorts.  In fact, 
the use of ticagrelor relative to clopidogrel use in Australia since 2012, more closely 
resembles reported practice in the US where limited uptake has been attributed to concerns 
regarding lack of benefit in the subgroup of US patients enrolled in the PLATO trial[32], 
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together with a Department of Justice investigation into the conduct of the study which did 
not report until 2014[33]. 
 
There are limitations of our study. A comparison of long-term outcomes of ACS patients 
based upon DAPT prescription at discharge has not been presented. However the 
cardioprotective effect of DAPT prescription at ACS hospital discharge is indisputable [34].  
In addition, variations in continued use of antiplatelet drugs in the short and long-term after 
discharge have not been reflected in this study. Being an observational study, there might 
be unmeasured biases that influenced physicians’ choice of therapies, including antiplatelet 
agents for ACS. Furthermore we did not collect specific reasons for failure to prescribe 
DAPT.  
 
CONCLUSION 
 
Our study illustrates the under-treatment with ideal antiplatelet therapy in high-risk ACS 
patient populations, and the independent predictors for non-prescription of DAPT at 
discharge following an ACS have been described in Australian practice. Additional strategies 
are required to bridge the treatment gap in antiplatelet management of ACS patients. 
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FIGURE LEGENDS 
 
Figure 1 
 
(a) Adjusted multivariable regression model built using logistic generalized estimating equations to 
identify predictors of DAPT non-prescription in those admitted with an ACS. Point estimates (OR, 
odds ratio) are indicated by points, and the 95% confidence interval (CI) are shown as bars. (b) 
Adjusted multivariable regression model built using logistic generalized estimating equations to 
identify predictors of DAPT non-prescription in those with ACS and medically managed. Point 
estimates (OR, odds ratio) are indicated by points, and the 95% confidence interval (CI) are shown as 
bars. *Reduced likelihood of DAPT prescription, **Increased likelihood of DAPT prescription. ACEI: 
Angiotensin-converting enzyme inhibitor, PCI: Percutaneous coronary intervention 
 
 
Figure 2 
 
(a) Percentage of patients prescribed with DAPT (dual antiplatelet therapy) or SAPT (single 
antiplatelet therapy) at time of discharge according to year of admission, and trend of second 
antiplatelet (clopidogrel, ticagrlor, prasugrel) discharge prescription over time. (b) Percentage of 
patients with DAPT (dual antiplatelet therapy) or SAPT (single antiplatelet therapy) prescription at 
time of discharge, in those medically managed, according to year of admission, and trend of 
second antiplatelet (clopidogrel, ticagrlor, prasugrel) discharge prescription over time.  
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
